<DOC>
	<DOCNO>NCT02649270</DOCNO>
	<brief_summary>The humanized recombinant anti-CD6 monoclonal antibody Injection ( T1h ) approve psoriasis India . The first trial China evaluate tolerability , safety , pharmacodynamic , pharmacokinetics preliminary efficacy T1h patient psoriasis .</brief_summary>
	<brief_title>Tolerability , Safety Pharmacokinetic Study Humanized Anti-CD6 Monoclonal Antibody Injection Chinese Psoriasis</brief_title>
	<detailed_description>The humanized recombinant anti-CD6 monoclonal antibody ( T1h ) develop whose ligand bind property original murine monoclonal antibody preserve CD6 molecule . T1h monoclonal antibody approve clinical study autoimmune disease Cuba India , psoriasis rheumatoid arthritis ( RA ) . Single multiple dose base tolerability , safety pharmacokinetic phase 1 Study Humanized Anti-CD6 Monoclonal Antibody Injection Chinese patient psoriasis , 40 patient enrol . They divide 4 group ( 0.2mg/kg , 0.4mg/kg , 0.8mg/kg , 1.6mg/kg ) group include 10 patient . First , dose single-dose administration gradually low dos 0.4mg/kg , 0.8mg/kg 1.6mg/kg multi-dose administration gradually low .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age range 18 55 year , male female ( less 3 patient dose group ) 2 . Patients chronic plaque psoriasis least 6 month ( patient inform consent ) without arthritis psoriasis 3 . BSA≥3 % PASI≥10 4 . PGA≥3 5 . Patients eligible washout period less time follow : 2 week topical retinoic acid glucocorticoid therapy 6 month retinoic acid kind drug therapy 2 week light therapy 4 week Psoralen combine UVA therapy 4 week methotrexate ( MTX ) , cyclophosphamide , cyclosporine immunosuppressive therapy 7 half life time period systemic immunosuppressive therapy 8 week Biological agent psoriasis therapy 6 . Fertile male female willing adopt contraceptive method ( e.g . hormonal pitch , intrauterine device , condom ) 7 . Patients voluntary sign write informed consent . 1 . The female pregnant , lactate show positive urine pregnancy reaction screen . 2 . Patients erythroderma pustular psoriasis . 3 . Patients receive glucocorticoid systemic drug therapy . 4 . Patients previously currently suffer autoimmune disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , inflammatory bowel disease , scleroderma , inflammatory myopathy , mixed connective tissue disease , overlap syndrome ) , suffer primary secondary immunodeficiency human immunodeficiency virus 5 . Patients active infection ( nail bed induce fungal infection exclude ) , chronic infection , tuberculosis history . 6 . Patients severe heart disease , heart failure , asthma , chronic obstructive pulmonary disease neuropsychiatric disease . 7 . Patients previously currently suffer tumor include solid tumor , hematologic malignancy carcinoma situ . 8 . Patients positive test hepatitis B surface antigen ( HBsAg ) , hepatitis C serology ( HCVAb ) human immunodeficiency virus ( HIVAb ) 9 . Patients Hemoglobin &lt; 90 g/L , white blood cell count &lt; 3.5 × 10^9 / L , neutrophil count &lt; 1.5 × 10^9 / L , platelet count &lt; 80 × 10^9 / L 10 . Patients double serum cereal third transaminase ( ALT ) glutamicoxaloacetic transaminase ( AST ) upper limit reference value serum creatinine value upper limit reference . 11 . Patients history drug abuse alcoholism 12 . Patients allergic recombinant biologic agent component proteins derive murine 13 . Patients surgery within three month plan surgery laser skin treatment within six month 14 . Patients receive vaccination within 28 day 15 . Patients receive experimental drug treatment within three month 16 . Patients suitable determined researcher</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetic Study</keyword>
	<keyword>preliminary pharmacodynamic study</keyword>
	<keyword>Humanized Anti-CD6 Monoclonal Antibody ( T1h )</keyword>
</DOC>